TY - JOUR
T1 - Patient-derived Xenograft models
T2 - An emerging platform for translational cancer research
AU - Hidalgo, Manuel
AU - Amant, Frederic
AU - Biankin, Andrew V.
AU - Budinská, Eva
AU - Byrne, Annette T.
AU - Caldas, Carlos
AU - Clarke, Robert B.
AU - de Jong, Steven
AU - Jonkers, Jos
AU - Mælandsmo, Gunhild Mari
AU - Roman-Roman, Sergio
AU - Seoane, Joan
AU - Trusolino, Livio
AU - Villanueva, Alberto
PY - 2014
Y1 - 2014
N2 - Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field.
AB - Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field.
UR - http://www.scopus.com/inward/record.url?scp=84906895091&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906895091&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-14-0001
DO - 10.1158/2159-8290.CD-14-0001
M3 - Article
AN - SCOPUS:84906895091
VL - 4
SP - 998
EP - 1013
JO - Cancer Discovery
JF - Cancer Discovery
SN - 2159-8274
IS - 9
ER -